Ligelizumab impairs <scp>IgE</scp> ‐binding to plasmacytoid dendritic cells more potently than omalizumab and restores <scp>IFN</scp> ‐α production and <scp>FOXP3</scp> <sup>+</sup> Treg generation-Reference-Cited by-同舟云学术

Ligelizumab impairs IgE ‐binding to plasmacytoid dendritic cells more potently than omalizumab and restores IFN ‐α production and FOXP3 ⁺ Treg generation

Published:2022-11-12 Issue:4 Volume:78 Page:1060-1072
ISSN:0105-4538
Container-title:Allergy
language:en
Short-container-title:Allergy

Author:

Benito‐Villalvilla Cristina¹^ORCID,de la Rocha‐Muñoz Andrés¹²^ORCID,López‐Abente Jacobo¹,Eggel Alexander³⁴^ORCID,Bottoli Iván⁵,Severin Thomas⁵,Woisetschläger Maximilian⁵,Palomares Oscar¹^ORCID

Affiliation:

1. Department of Biochemistry and Molecular Biology School of Chemistry Complutense University Madrid Spain

2. Autonomous University of Madrid Madrid Spain

3. Department of BioMedical Research University of Bern Bern Switzerland

4. Department of Rheumatology and Immunology University Hospital of Bern Bern Switzerland

5. Novartis Pharma AG Basel Switzerland

Funder

Ministerio de Ciencia e Innovación

Novartis Pharma

Novartis

Universidad Complutense de Madrid

Publisher